Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid in infants with severe osteogenesis imperfecta
2011-000745-21Phase 3Terminated
- Sponsor
- Shriners Children's
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zoledronic acid in osteogenesis imperfecta (OI), sponsored by Shriners Children's. Primary endpoint: Change in lumbar spine bone mineral density Z-score at month 24. Started Sep 2012; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2011-000745-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000745-21.